These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1732631)

  • 1. Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984.
    Neubauer BL; Merriman RL; Best KL; Goode RL; Sarosdy MF; Tanzer LR; Howbert JJ
    J Urol; 1992 Feb; 147(2):500-4. PubMed ID: 1732631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
    Neubauer BL; Best KL; Counts DF; Goode RL; Hoover DM; Jones CD; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
    Prostate; 1995 Oct; 27(4):220-9. PubMed ID: 7479389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
    Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
    Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
    Neubauer BL; McNulty AM; Chedid M; Chen K; Goode RL; Johnson MA; Jones CD; Krishnan V; Lynch R; Osborne HE; Graff JR
    Cancer Res; 2003 Sep; 63(18):6056-62. PubMed ID: 14522935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the rat.
    Neubauer BL; Bemis KG; Best KL; Goode RL; Merriman RL; Smith GF; Tanzer LR; Hoover DM
    Prostate; 1986; 8(3):265-76. PubMed ID: 3703746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
    Neubauer BL; Bemis KG; Best KL; Goode RL; Hoover DM; Smith GF; Tanzer LR; Merriman RL
    J Urol; 1986 Jan; 135(1):163-6. PubMed ID: 3941458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antitumor properties of selenocoxib-1 against rat prostate adenocarcinoma cells.
    Desai D; Sinha I; Null K; Wolter W; Suckow MA; King T; Amin S; Sinha R
    Int J Cancer; 2010 Jul; 127(1):230-8. PubMed ID: 19918950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
    Sarosdy MF; Higdon AL; Demoor CA
    J Urol; 1996 Jun; 155(6):2085-9. PubMed ID: 8618341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats.
    Heinrich JE; Pollard M; Wolter WA; Liang Z; Song H; Rosen ED; Suckow MA
    Cancer Immunol Immunother; 2007 May; 56(5):725-30. PubMed ID: 16953436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro.
    Cadieux PA; Mikolajczak SA; Reeves J; Strathdee C; Reid G; Panchal CJ; Clarke MW
    Cancer Invest; 2006; 24(3):246-55. PubMed ID: 16809150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer.
    Oades GM; Dredge K; Kirby RS; Colston KW
    BJU Int; 2002 Oct; 90(6):607-16. PubMed ID: 12230626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
    Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS
    Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-(methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients.
    Morré DJ; Reust T
    J Bioenerg Biomembr; 1997 Jun; 29(3):281-9. PubMed ID: 9298713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes.
    Morré DJ; Wu LY; Morré DM
    Biochim Biophys Acta; 1995 Nov; 1240(1):11-7. PubMed ID: 7495842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton release from HeLa cells and alkalization of cytoplasm induced by diferric transferrin or ferricyanide and its inhibition by the diarylsulfonylurea antitumor drug N-(4-methylphenylsulfonyl)-N'-(4-cholorophenyl) urea (LY181984).
    Sun E; Lawrence J; Morré DM; Sun I; Crane FL; MacKellar WC; Morré DJ
    Biochem Pharmacol; 1995 Oct; 50(9):1461-8. PubMed ID: 7503797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dimethylsulfoxide on the proliferation and glycosaminoglycan synthesis of rat prostate adenocarcinoma cells (PAIII) in vitro: isolation and characterization of DMSO-resistant cells.
    Kaneski CR; Constantopoulos G; Brady RO
    Prostate; 1991; 18(1):47-58. PubMed ID: 1987579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bropirimine immunotherapy of rodent prostate cancer.
    Sarosdy MF
    Eur Urol; 1997; 31 Suppl 1():5-9. PubMed ID: 9076480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NADH oxidase activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) at an external site.
    Morré DJ
    Biochim Biophys Acta; 1995 Dec; 1240(2):201-8. PubMed ID: 8541291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer.
    Naik HR; Lehr JE; Pienta KJ
    Anticancer Res; 1994; 14(6B):2617-9. PubMed ID: 7872690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of a cell-surface NADH oxidase to the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenylurea) (LY181984) modulated by redox.
    Morré DJ; Wu LY; Morré DM
    Biochim Biophys Acta; 1998 Mar; 1369(2):185-92. PubMed ID: 9518604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.